The Investigation and Treatment of Diabetic Gastroparesis |
| |
Authors: | Mohit Kumar Adam Chapman Saad Javed Uazman Alam Rayaz A Malik Shazli Azmi |
| |
Affiliation: | 1. Royal Albert Edward Infirmary Wrightington, Wigan and Leigh National Health Service Foundation Trust, Wigan, United Kingdom;2. Aintree University Hospital National Health Service Foundation Trust, Liverpool, United Kingdom;3. Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom;4. Division of Endocrinology, Diabetes and Gastroenterology, University of Manchester, Manchester, United Kingdom;5. Diabetes and Endocrinology Research and the Pain Research Institute, Department of Eye and Vision Sciences, Institute of Ageing and Chronic Disease, University of Liverpool and Aintree University Hospital NHS Foundation Trust, Liverpool, United Kingdom;6. Department of Diabetes and Endocrinology, Royal Liverpool and Broadgreen University NHS Hospital Trust, Liverpool, United Kingdom;7. Weill Cornell Medicine-Qatar, Doha, Qatar;8. Manchester Diabetes Centre, Manchester University Foundation Trust, Manchester, United Kingdom |
| |
Abstract: |
PurposeThis review provides an update on the investigations and treatment options for gastroparesis.MethodsA comprehensive literature search of Medline, PubMed, Embase and OVID was conducted which included all systematic reviews and research articles that focused on the diagnosis, investigations and management diabetic gastroparesis.FindingsDietary modifications and pharmacologic treatment with prokinetics to increase gastric motility form the mainstay of treatment. However, the use of prokinetics is limited by adverse effects and serious adverse effects, leaving metoclopramide as the only drug approved by the US Food and Drug Administration for the treatment of gastroparesis. Newer therapies, including motilin receptor agonists, ghrelin receptor agonists, and neurokinin receptor antagonists, are currently being investigated. Transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy provide mechanical options for intervention, and surgical interventions in severe intractable gastroparesis include laparoscopic pyloroplasty or gastrectomy.ImplicationsAdvances to better understand the pathophysiology and management of diabetic gastroparesis have been limited, especially with discordance between symptoms and severity of delay in gastric emptying. Established treatment options are limited; however, recent pharmacologic and surgical interventions show promise. |
| |
Keywords: | Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Gastroparesis Microvascular |
本文献已被 ScienceDirect 等数据库收录! |
|